Endocrine Abstracts

Introduction: The SGLT-2 inhibitors (InibSGLT2) are the newest class of non-insulin antidiabetic drugs (ANI) for type 2 diabetes mellitus (T2DM) treatment. Currently is only available in Portugal, dapagliflozin. This pharmacological class have shown benefits in metabolic control (reduction of 0.5–0.8% HbA1c) and in weight loss (1–3 kg).

Objective: Evaluate the impact of InibSGLT2 in patients with T2DM followed in a Diabetes department.

Methods: Retrospective study of patients with T2DM followed in clinic, treated with Dapagliflozin since December 2014 to December 2015. We evaluated demographic data, antidiabetic medication used prior to Dapagliflozin introduction, metabolic control and weight at 0, 3 and 6 months. Data analyzed by methods of descriptive statistics.

Results: We observed 78 patients, 64.1% male, mean age 64±10 years. Average initial HbA1c was 8.1% (6.5–11.7%) and initial weight was 92.7 kg (72–122 kg). 72.9% were exclusively treated with ANI and 27.1% with insulin therapy. Of patients treated exclusively with ANI, 14.8% were treated with 1 ANI, 40.7% with 2 ANI, 37.0% with 3 ANI and 7.4% with 4 ANI. There was an exchange in pharmacological classes in 13.5% of patients while others had an add-on therapy. 10.9% of patients abandoned therapy, 75% because of genital-urinary complaints. 28.2% have no reassessment after introduction of Dapagliflozin, 53.8% after 3 months and 10.3% after 6 months. After 3 months there was a decreased in HbA1c of 0.57% (−2.1%;+1.2%), with 21.8% patients having an increase in HbA1c. At 6 months, there was an average reduction of 0.25% (−0.8;+0.3%). Weight reduction at 3 months was on average −1.99 kg (−6;+1), of which 14.8% had increased weight. At 6 months, there was an average reduction of −5.2 kg (−10;−0.4).

Conclusions: We conclude that patients with DM2 treated with InibSGLT2 obtained benefits especially in weight loss and metabolic control immediately. The extension of this analysis will assess long-term results.